Orthocell has identified a promising new application for its flagship Remplirâ„¢ nerve repair device – for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP).
Remplirâ„¢ Real World Evidence study delivers compelling 81% success rate
Orthocell has today released interim results from a new Remplirâ„¢ Real World Evidence study, demonstrating an overall treatment success rate of 81.1% following nerve repair procedures.
Commercialisation of Remplirâ„¢ into US Market Continues to Build Momentum
Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplirâ„¢ in the US.
Orthocell Announces Changes to its Board of Directors
Orthocell has today announced some important changes to its Board of Directors.
First US Sales Revenue from Remplirâ„¢
Orthocell has today reached a critical milestone in the commercialisation of Remplirâ„¢ in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.
OCC Quarterly Report | Quarter ended 30 June 2025
Orthocell has today released its Quarterly Report for the period ended 30 June 2025.
Orthocell Achieves a Record $2.73m in Revenue for June Quarter
Orthocell has announced record quarterly revenue of $2.73 million for the June quarter – our fifth consecutive quarter of record revenue growth.
First US Surgical Use of Remplirâ„¢Â
Orthocell recorded first use of Remplirâ„¢ in the US overnight, which is an important step in establishing surgical experience and knowledge of the product.Â
Breakthrough Study Confirms Remplirâ„¢ Superiority Over Standard US Nerve Repair Technique
Orthocell has today announced interim results from a new study demonstrating that Remplirâ„¢ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques.
Stockhead | Interview with Dr Ian Valerio
During his visit to Australia last week for Orthocell’s annual nerve repair and reconstruction symposium, US reconstructive surgeon Dr Ian Valerio made the time to speak with Stockhead’s Tylah Tully about the significant global opportunity for Remplir, following recent FDA approval.